Krystexxa®

Understanding Krystexxa® 

Krystexxa® (pegloticase) is a medication used to treat chronic gout that is refractory (unresponsive) to standard therapies. It works by breaking down uric acid in the blood, helping to prevent and reduce painful gout symptoms. Krystexxa® is a biologic enzyme therapy that converts uric acid into a more easily excreted substance, helping to lower uric acid levels and reduce gout flares in patients who have not responded to conventional treatments.

How Krystexxa® Works:

• Breaks down uric acid into a form that can be easily excreted.
• Reduces uric acid levels to help prevent gout attacks.
• Lowers the risk of long-term joint damage caused by chronic gout.

FDA Approval:

• September 14, 2010 – Approved for the treatment of chronic refractory gout

For more information, please visit the Krystexxa® patient website and speak with your healthcare provider to determine if Krystexxa® is the right treatment option for you.